Healthcare resource utilization, total costs, and comorbidities among patients with myotonic dystrophy using U.S. insurance claims data from 2012 to 2019

Table 3 Most impactful comorbidities among patients with cDM compared with matched controls for the 12-month follow-up period^a^,b

ICD-9 or ICD-10 code	Description	cDM cohort (N = 236)		Fold change^c
ICD-9 or ICD-10 code	Description	n	%	Fold change^c
R63	Symptoms and signs concerning food and fluid intake	82	34.7	10.3
Z93	Artificial opening status	76	32.2	76.0
R62	Lack of expected normal physiological development in childhood and adults	66	28.0	8.3
783	Nutrition/metabolism/development symptoms	65	27.5	8.1
R06	Abnormalities of breathing	65	27.5	2.8
R13	Aphagia and dysphagia	62	26.3	62.0
787	GI system symptoms	54	22.9	4.2
J96	Respiratory failure, not elsewhere classifies	49	20.8	24.5
P94	Disorders of muscle tone of newborn	48	20.3	48.0
J98	Other respiratory disorders	47	19.9	11.8
R09	Other symptoms and signs involving the circulatory and respiratory systems	47	19.9	2.9
K21	Gastro-esophageal reflux disease	46	19.5	9.2
R29	Other symptoms and signs involving the nervous and musculoskeletal systems	42	17.8	42.0
Q21	Congenital malformations of cardiac septa	42	17.8	7.0
Z99	Dependence on enabling machines and devices, not elsewhere classified	40	16.9	40.0

^aExcludes ICD9 359 (muscular dystrophies) and ICD10 G71 (primary disorders of muscle) as these are the ICD codes for inclusion in the study
^bAffects more than 5% of the DM Cohort and at least 2X more than the controls with P value < 0.0001 during the 12-month follow-up period
^cFold change is the multiple of how many more times the disease cohort is affected by the specific comorbidity compared to controls

ISSN: 1750-1172